Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 2881-2889

  Han, Xu ^a   Zhao, Jing ^a   Ji, Yuan ^a   Xu, Xuefeng ^a   Lou, Wenhui ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CK19; KIT; Neuroendocrine tumor; Pancreas

Indexed keywords

EID: 84885423314     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0850-8     Document Type: Article

References (27)

1. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753-81.
2. Clawson GA. From devils to jobs: tracking neuroendocrine tumors. Transl Cancer Res. 2013;2:3-5.
3. Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273-81.
4. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrinol Relat Cancer. 2010;17:909-18.
5. Chen M, Van Ness M, Guo Y, et al. Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2012;3:182-8.
6. Chen WQ, Zeng HM, Zheng RS, Zhang SW, He J. Cancer incidence and mortality in China, 2007. Chin J Cancer Res. 2012;24:1-8.
7. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-23.
8. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-13.
9. Zhang L, Smyrk TC, Oliveira AM, et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol. 2009;33:1562-9.
10. Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med. 2013;1:6.
11. Oliver-Krasinski JM, Stoffers DA. On the origin of the beta cell. Genes Dev. 2008;22:1998-2021.
12. Ashman LK. The biology of stem cell factor and its receptor c-kit. Int J Biochem Cell Biol. 1999;31:1037-51.
13. Linnekin D, Keller JR, Ferris DK, et al. Stem cell factor induces phosphorylation of a 200 kDa protein which associates with c-kit. Growth Factors. 1995;12:57-67.
14. Li J, Quirt J, Do HQ, et al. Expression of c-Kit receptor tyrosine kinase and effect on beta-cell development in the human fetal pancreas. Am J Physiol Endocrinol Metab. 2007;293:E475-83.
15. Bouwens L, Lu WG, De Krijger R. Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia. 1997;40:398-404.
16. Piper K, Brickwood S, Turnpenny LW, et al. Beta cell differentiation during early human pancreas development. J Endocrinol. 2004;181:11-23.
17. Bouwens L. Cytokeratins and cell differentiation in the pancreas. J Pathol. 1998;184:234-9.
18. Real FX, Vila MR, Skoudy A, et al. Intermediate filaments as differentiation markers of exocrine pancreas. II. Expression of cytokeratins of complex and stratified epithelia in normal pancreas and in pancreas cancer. Int J Cancer. 1993;54:720-7.
19. Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol. 2004;28:1145-53.
20. La Rosa S, Rigoli E, Uccella S, et al. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology. 2007;50:597-606.
21. Crippa S, Partelli S, Boninsegna L, et al. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Ann Oncol. 2012;23:1928.
22. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
23. Yasuda A, Sawai H, Takahashi H, et al. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer. 2006;5:46.
24. Sammarco I, Capurso G, Coppola L, et al. Expression of the protooncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients. Int J Color Dis. 2004;19:545-53.
25. Nio Y, Omori H, Hashimoto K, et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas. Anticancer Res. 2005;25:3523-9.
26. Hong SM, Hwang I, Song DE, et al. Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. Mod Pathol. 2007;20:562-9.
27. Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256:321-5.